Prestige Consumer Healthcare Inc. $PBH Shares Sold by Amundi

Key Points

• Amundi has reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.6%, now holding 20,630 shares valued at approximately $1.74 million.
• The company reported $0.95 EPS for the last quarter, missing estimates, with revenue down 6.6% year-over-year.
• Analysts have downgraded Prestige Consumer Healthcare, with Zacks Research shifting its rating from "hold" to "strong sell".

Amundi decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,630 shares of the company's stock after selling 5,039 shares during the quarter. Amundi's holdings in Prestige Consumer Healthcare were worth $1,744,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PBH. Opal Wealth Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 1st quarter worth approximately $38,000. McIlrath & Eck LLC grew its stake in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares during the period. Costello Asset Management INC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter valued at $112,000. GAMMA Investing LLC grew its stake in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after acquiring an additional 496 shares during the period. Finally, KBC Group NV grew its stake in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after acquiring an additional 151 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PBH shares. Zacks Research cut shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Thursday, September 4th. Canaccord Genuity Group cut their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Trading Up 0.5%

NYSE:PBH traded up $0.32 during mid-day trading on Thursday, reaching $64.14. The company's stock had a trading volume of 510,020 shares, compared to its average volume of 569,389. The company's fifty day simple moving average is $69.34 and its two-hundred day simple moving average is $78.64. The stock has a market cap of $3.16 billion, a P/E ratio of 15.06, a P/E/G ratio of 2.02 and a beta of 0.46. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. Prestige Consumer Healthcare Inc. has a twelve month low of $61.93 and a twelve month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. During the same quarter in the previous year, the business posted $0.90 earnings per share. The business's quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.